General Information of Drug (ID: DM95T5Z)

Drug Name
Sapablursen Drug Info
Indication
Disease Entry ICD 11 Status REF
Polycythemia vera 2A20.4 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DM95T5Z

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Preclinical Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
IONIS-TMPRSS6-LRx DM7VJE1 Beta thalassemia 3A50.2 Phase 2 [3]
SLN124 DMIAOU6 Beta thalassemia 3A50.2 Phase 1 [4]
ALN-TMP DMW7XEU Beta thalassemia 3A50.2 Preclinical [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
TMPRSS6 messenger RNA (TMPRSS6 mRNA) TTNIUKC TMPS6_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT05143957) A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV). U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Ionis
3 Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
4 SLN124, a GalNAc-siRNA Conjugate Targeting TMPRSS6, Efficiently Prevents Iron Overload in Hereditary Haemochromatosis Type 1. Hemasphere. 2019 Oct 1;3(6):e301.
5 Targeting iron metabolism in drug discovery and delivery. Nat Rev Drug Discov. 2017 Jun;16(6):400-423.